Pharmaceutical
Biopharmaceutical
Manufacturing
Bristol-Myers Squibb
$47.279876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$47.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.49 (-1.04%) Today
+$0.45 (0.97%) After Hours
Why Robinhood?
You can buy or sell BMY and other stocks, options, ETFs, and crypto commission-free!
About
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. Read More The company was founded in August 1933 and is headquartered in New York, NY.
Employees
23,300
Headquarters
New York, New York
Founded
1933
Market Cap
77.38B
Price-Earnings Ratio
14.81
Dividend Yield
3.10
Average Volume
11.82M
High Today
$47.54
Low Today
$46.79
Open Price
$47.41
Volume
3.01M
52 Week High
$63.69
52 Week Low
$44.30
Collections
Pharmaceutical
Biopharmaceutical
Manufacturing
Research And Development
Health
Biotechnology
Technology
Business Services
News
BenzingaMay 22
Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond
Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what immunotherapy means: it's a type of cancer treatment that uses the body's immune system to put up a fight against cancer cells. Merck's Keytruda, or pembrolizumab, and BMY's Opdivo, or nivolumab, are both human, programmed deat...
Price Paid on Robinhood
5% Lower
Right Now
52 Week Low
$44.30
Average Price Paid
$49.79
52 Week High
$63.69
Earnings
$0.67
$0.81
$0.96
$1.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 25, Pre-Market